News
ASLAN Pharmaceuticals Announces $20m Private Placement Led by BVF Partners L.P. With The Potential to Receive up to an Additional $80m
February 24, 2023
San Mateo, California, and Singapore, February 24, 2023 – ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has entered into a definitive purchase agreement (“Purchase Agreement”) to raise gross proceeds of approximately $20 million resulting from the sale of its ordinary shares (or pre-funded warrants) and accompanying purchase warrants, at a purchase price of $0.178 per ordinary share (or the equivalent of $0.89 per American Depositary Share (“ADS”)) to BVF Partners L.P., K2 HealthVentures and certain existing investors (the “Investors”). In addition, ASLAN will have the potential to receive up to an additional $80 million if all purchase warrants being issued in connection with the Purchase Agreement are fully exercised.
Alto Neuroscience Announces $60 Million in Additional Financing
January 30, 2023
LOS ALTOS, Calif., January 30, 2023 – Alto Neuroscience Inc. today announced a $25 million equity investment by new investor, Alpha Wave Ventures. This brings Alto’s total Series B funding to approximately $60 million and total equity capital raised to approximately $100 million since the company was founded in 2019. In addition, Alto recently entered into a credit facility with K2 HealthVentures for up to $35 million, allowing access to additional capital and flexibility as the company advances its clinical-stage pipeline. Funding to date will support Alto through a total of four Phase 2 readouts with four novel drug candidates across three indications, as well as the continued evolution of Alto’s Precision Psychiatry Platform™.
89bio Provides Business Update and Outlook for 2023
January 04, 2023
SAN FRANCISCO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today provided a corporate update, including its roadmap for advancing pegozafermin in 2023.
DispatchHealth Raises More Than $330 Million to Expand Its Technology-Enabled Ecosystem of High Acuity Care in the Home
November 23, 2022
DENVER, Nov. 23, 2022 /PRNewswire/ -- DispatchHealth, the nation’s first comprehensive in-home, high acuity medical care provider, today announced it has raised more than $330 million in combined equity and debt financing. The equity round of $259 million was led by Optum Ventures, with participation from new investors Adams Street Partners, Blue Shield of California, among others, and continued support from existing investors Humana, Echo Health Ventures, Questa Capital and Oak HC/FT. K2 HealthVentures, Silicon Valley Bank and SVB Capital provided debt financing of $75 million, with up to an additional $75 million available for growth initiatives, bringing the total raised to more than $400 million.
Inari Raises $124 Million to Design Seeds for a More Sustainable Food System
October 04, 2022
CAMBRIDGE, Mass., October 4, 2022 — Inari today announced that it secured $124 million in the successful completion of its latest fundraise. Working to deliver nature-positive solutions, the SEEDesign™ company’s cumulative equity raised now totals $475 million. The investment will further advance Inari’s leading position in multiplex gene-edited seed technology, support expansion of company product development and ultimately deliver new value in the commercial seed market.
VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures
September 15, 2022
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced it has entered into a refinanced and upsized debt facility of up to $100 million with its existing lender, K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.
TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures
September 12, 2022
WALTHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that it has entered into a debt financing facility for up to $60 million with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.
Elevation Oncology Secures $50 Million Loan Facility with K2 HealthVentures
July 28, 2022
NEW YORK, July 28, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers, today announced that it has secured a $50 million senior secured loan facility from funds managed by K2 HealthVentures, a leading healthcare-focused investment firm. The initial proceeds from the facility will primarily support the exclusive license of EO-3021 (SYSA1801) outside of Greater China from CSPC Pharmaceutical Group and the execution of the Company's pipeline.
Inozyme Pharma Secures Flexible Debt Facility for up to $70 Million with K2 HealthVentures
July 26, 2022
BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced that it has entered into a debt financing facility for up to $70 million with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.
Ribon Therapeutics Secures $50 Million in Growth Capital from K2 HealthVentures
April 26, 2022
Cambridge, MA – April 26, 2022 – Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced a $50 million debt financing facility from K2 HealthVentures (K2HV), a healthcare and life sciences-focused investment firm. Proceeds will be used to continue clinical and preclinical development of Ribon’s portfolio of selective, small molecule inhibitors to NAD+-utilizing enzymes.
Oncorus Announces Debt Capital Facility with K2 HealthVentures with $20 Million Funded at Closing, Relocation of Corporate Headquarters and Extension of Cash Runway
April 05, 2022
CAMBRIDGE, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that it has entered into a loan and security agreement with K2 HealthVentures (K2HV), a healthcare focused specialty finance company. Also today, Oncorus announced plans to relocate all its operations to its facility in Andover, Massachusetts in the fourth quarter of 2022, to allow research, process development and Good Manufacturing Practice (GMP)-compliant manufacturing to occur all in one facility. As a result of the term loan facility and operations relocation, as well as other initiatives to increase operational efficiency, Oncorus now expects its cash, cash equivalents and investments to fund its capital expenditures and operating expenses into early 2024.
PlateletBio Completes $75.5M Series B Financing
November 08, 2021
WATERTOWN, Mass.--(BUSINESS WIRE)--PlateletBio, a preclinical-stage biotechnology company pioneering an entirely new platform of allogeneic cell therapies based on platelet biology, today announced that it has raised $75.5 million in Series B financing. The round includes new investors SymBiosis, K2 HealthVentures and Oxford Finance as well as participation from existing investors Ziff Capital Partners and Qiming Venture Partners.
Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change
October 18, 2021
CAMBRIDGE, Mass., Oct. 13, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company unlocking the potential of natural systems to accelerate the transition to sustainable agriculture to urgently address climate change, has entered into a $50 million loan and security agreement with K2 HealthVentures (K2HV), a healthcare and life sciences-focused investment firm.
Aptinyx Secures $50 Million Growth Capital Credit Facility from K2 HealthVentures
September 22, 2021
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has entered into a $50 million loan facility and security agreement with K2 HealthVentures (K2HV). The funds will provide general growth capital as Aptinyx advances its late-stage clinical pipeline of novel NMDA modulators.
ASLAN Pharmaceuticals Announces Loan Facility Providing Up to $45 Million From K2 HealthVentures
July 13, 2021
ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has closed a secured loan facility provided by K2 HealthVentures (K2HV). Under the terms of the facility, K2HV will provide ASLAN up to $45 million of secured debt financing. The facility consists of a $20 million initial term loan funded at closing, with the remaining $25 million subject to certain terms and conditions.
Vesta Healthcare Announces $65M in Growth Capital to Transform Care for High Needs Members and their Caregivers
April 06, 2021
Vesta Healthcare, a 24/7 clinical provider group and digital health platform, dedicated to supporting high needs members at home and connecting their caregivers’ insights to the rest of the care team, announced the raise of $65M in growth capital. The financing was led by Deerfield Management Company with participation from existing investors Oak HC/FT, Kaiser Permanente Ventures, Lux Capital, Generator Ventures, Nationwide, CareCentrix and Epstein Partners as well as new participation from K2 HealthVentures and an unnamed investor.
Click Therapeutics Secures $30M in Growth Capital from K2 HealthVentures to Expand Operations
December 01, 2020
Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ solutions as prescription medical treatments, today announced $30 million in debt financing from K2 HealthVentures (K2HV), a healthcare-focused specialty finance company, to accelerate commercialization of its leading smoking cessation solution, Clickotine™, and to advance its pipeline of clinically-validated digital therapeutics.
Cricket Health Names New CEO Robert Sepucha, Secures $15 Million in Growth Capital from K2 HealthVentures to Expand Operations
October 22, 2020
Cricket Health, a comprehensive kidney care provider with a personalized, evidence-based approach to managing kidney disease, today announced that co-founder Arvind Rajan has been named Executive Chairman of the Board of Directors and Robert Sepucha has been appointed Rajan's successor as the company's CEO.The news comes as Cricket announces $15 million in debt financing from K2 HealthVentures (K2HV), a healthcare-focused specialty finance company, which will help the company further expand its innovative kidney care model to more people across the country through additional payer partnerships.
COLORESCIENCE® ANNOUNCES SUCCESSFUL COMPLETION OF $30 MILLION DEBT FINANCING-SUPPORTING CONTINUED GROWTH IN CORE CHANNELS
September 14, 2020
Colorescience, an industry- leading, science-based, and health-focused skincare company announced today the successful completion of a $30 Million debt financing with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company. This debt facility strengthens the Company’s balance sheet in a non-dilutive fashion and increases financial flexibility to support continued growth in its core channels
Corbus Pharmaceuticals Strengthens Balance Sheet with up to $121 Million in New Capital
July 29, 2020
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced it has received an aggregate of $71 million in gross proceeds from its at-the-market (“ATM") offering coupled with the execution of a $50 million debt financing facility with K2 HealthVentures (“K2HV”), a healthcare-focused specialty finance company.
FLEXIBLE, PATIENT CAPITAL
A unique capital structure that enables creative and adaptive financing solutions
